Medication-Induced Movement Disorders

What are Medication-Induced Movement Disorders?

Medication-Induced Movement Disorders are abnormal movements that develop as side effects of medications, particularly psychiatric medications such as antipsychotics, antidepressants, and mood stabilisers. These disorders can range from mild and temporary to severe and potentially permanent, significantly impacting a person's quality of life and ability to function in daily activities.

These movement disorders are important to recognise because they can be mistaken for symptoms of the underlying mental health condition being treated, may lead to medication non-adherence, and in some cases require immediate medical intervention. Understanding these conditions helps ensure appropriate treatment and management of both the mental health condition and the movement side effects.

Types of Medication-Induced Movement Disorders

Extrapyramidal Symptoms (EPS)

• Acute Dystonia: Sudden, involuntary muscle contractions causing abnormal postures or movements.
• Parkinsonism: Symptoms similar to Parkinson's disease, including tremor, rigidity, and slowed movements.
• Akathisia: Subjective feeling of restlessness with inability to sit still or remain motionless.
• Tardive Dyskinesia: Late-onset involuntary movements, typically affecting the face, mouth, and tongue.

Neuroleptic Malignant Syndrome (NMS)

• Life-Threatening Condition: Rare but potentially fatal reaction to antipsychotic medications.
• Muscle Rigidity: Severe muscle rigidity and stiffness throughout the body.
• Hyperthermia: Dangerously high body temperature and fever.
• Autonomic Instability: Changes in blood pressure, heart rate, and breathing.

Tardive Syndromes

• Tardive Dyskinesia: Involuntary movements of face, mouth, tongue, and sometimes limbs.
• Tardive Dystonia: Sustained muscle contractions causing abnormal postures.
• Tardive Akathisia: Persistent restlessness that develops after long-term medication use.
• Tardive Tremor: Tremor that develops after prolonged medication exposure.

Serotonin Syndrome

• Serotonin Toxicity: Potentially life-threatening condition from excessive serotonin activity.
• Muscle Rigidity: Muscle stiffness and rigidity, particularly in the legs.
• Tremor and Clonus: Rapid muscle contractions and tremor.
• Altered Mental Status: Confusion, agitation, and altered consciousness.

Causative Medications

Antipsychotic Medications

• Typical Antipsychotics: Haloperidol, chlorpromazine, fluphenazine - higher risk of EPS.
• Atypical Antipsychotics: Risperidone, olanzapine, quetiapine - lower but still present risk.
• Long-Acting Injections: Depot formulations may have prolonged effects.
• Dose-Related Risk: Higher doses generally associated with increased risk.

Antidepressant Medications

• SSRIs: Can cause akathisia, tremor, and contribute to serotonin syndrome.
• SNRIs: Similar risks to SSRIs with additional movement-related side effects.
• Tricyclic Antidepressants: Can cause tremor and other movement symptoms.
• MAOIs: Risk of serotonin syndrome when combined with other serotonergic medications.

Other Psychiatric Medications

• Mood Stabilisers: Lithium can cause tremor; valproate can cause tremor and hair loss.
• Anti-Anxiety Medications: Benzodiazepines can cause ataxia and coordination problems.
• ADHD Medications: Stimulants can cause tics and movement abnormalities.
• Sleep Medications: Some can cause morning grogginess and coordination problems.

Non-Psychiatric Medications

• Antiemetics: Metoclopramide and prochlorperazine can cause EPS.
• Calcium Channel Blockers: Some can cause parkinsonism.
• Antihistamines: Some can cause movement symptoms, particularly in elderly.
• Antibiotics: Certain antibiotics can interact with psychiatric medications.

Clinical Presentation

Acute Dystonia

• Sudden Onset: Usually occurs within hours to days of starting medication.
• Muscle Spasms: Involuntary muscle contractions affecting face, neck, or limbs.
• Oculogyric Crisis: Eyes rolling upward and getting stuck in that position.
• Laryngeal Dystonia: Throat muscle spasms that can affect breathing and swallowing.

Drug-Induced Parkinsonism

• Tremor: Resting tremor, typically starting in hands or fingers.
• Rigidity: Muscle stiffness and resistance to passive movement.
• Bradykinesia: Slowed movements and difficulty initiating movement.
• Postural Instability: Problems with balance and coordination.

Akathisia

• Subjective Restlessness: Internal feeling of restlessness and need to move.
• Motor Restlessness: Inability to sit still, pacing, rocking, or fidgeting.
• Anxiety and Agitation: Increased anxiety and agitation related to restlessness.
• Sleep Disturbance: Difficulty sleeping due to restlessness.

Tardive Dyskinesia

• Facial Movements: Involuntary movements of face, mouth, and tongue.
• Limb Movements: Choreiform movements of arms and legs.
• Trunk Movements: Twisting or writhing movements of the trunk.
• Respiratory Dyskinesia: Abnormal breathing patterns or sounds.

Risk Factors

Patient-Related Factors

• Age: Elderly patients at higher risk for most movement disorders.
• Gender: Women may be at higher risk for some tardive syndromes.
• Genetic Factors: Genetic variations affecting drug metabolism.
• Medical Comorbidities: Neurological conditions, diabetes, and other medical conditions.

Medication-Related Factors

• Medication Type: Typical antipsychotics carry higher risk than atypicals.
• Dose and Duration: Higher doses and longer duration increase risk.
• Rapid Dose Changes: Quick increases or decreases in medication doses.
• Polypharmacy: Multiple medications that can interact or compound risks.

Clinical Factors

• Previous Episodes: History of movement disorders increases future risk.
• Substance Use: Alcohol or drug use can increase risk or severity.
• Nutritional Status: Poor nutrition may increase vulnerability.
• Stress and Illness: Physical or emotional stress may trigger symptoms.

Assessment and Diagnosis

Clinical Evaluation

• Detailed History: Comprehensive medication history and timeline of symptoms.
• Physical Examination: Thorough neurological examination and movement assessment.
• Symptom Documentation: Detailed documentation of movement abnormalities.
• Functional Assessment: Assessment of impact on daily functioning and quality of life.

Assessment Tools

• Abnormal Involuntary Movement Scale (AIMS): Standardised assessment for tardive dyskinesia.
• Simpson-Angus Scale (SAS): Assessment tool for drug-induced parkinsonism.
• Barnes Akathisia Rating Scale (BARS): Standardised assessment for akathisia.
• Extrapyramidal Symptom Rating Scale (ESRS): Comprehensive assessment of EPS.

Differential Diagnosis

• Primary Movement Disorders: Distinguishing from Parkinson's disease, essential tremor, etc.
• Psychiatric Symptoms: Differentiating from agitation, anxiety, or psychotic symptoms.
• Medical Conditions: Ruling out other medical causes of movement abnormalities.
• Substance-Related: Considering effects of alcohol, drugs, or other substances.

Monitoring Protocols

• Baseline Assessment: Pre-treatment assessment of movement and neurological function.
• Regular Monitoring: Ongoing monitoring during treatment with at-risk medications.
• Standardised Assessments: Using standardised tools for consistent monitoring.
• Documentation: Careful documentation of assessments and any changes.

Treatment and Management

Immediate Interventions

• Medication Adjustment: Reducing dose or discontinuing causative medication when possible.
• Anticholinergic Medications: Benztropine or trihexyphenidyl for acute dystonia and parkinsonism.
• Emergency Treatment: Immediate treatment for severe dystonia or NMS.
• Supportive Care: Supportive care for symptoms and complications.

Specific Treatments

For Acute Dystonia

• Anticholinergics: Benztropine or diphenhydramine for immediate relief.
• Benzodiazepines: Lorazepam for muscle relaxation and anxiety.
• Prevention: Prophylactic anticholinergics for high-risk patients.

For Drug-Induced Parkinsonism

• Anticholinergics: First-line treatment for drug-induced parkinsonism.
• Amantadine: Alternative treatment, particularly for tremor.
• Dose Reduction: Reducing antipsychotic dose when clinically feasible.

For Akathisia

• Beta-Blockers: Propranolol as first-line treatment for akathisia.
• Anticholinergics: May be helpful, particularly if combined with other EPS.
• Benzodiazepines: For anxiety and agitation associated with akathisia.
• Mirtazapine: Antidepressant that may help with akathisia.

For Tardive Dyskinesia

• VMAT2 Inhibitors: Valbenazine and deutetrabenazine as FDA-approved treatments.
• Medication Discontinuation: Gradual discontinuation of causative medication when possible.
• Antioxidants: Vitamin E and other antioxidants may have some benefit.
• Botulinum Toxin: For localised tardive dystonia.

Long-Term Management

• Medication Optimisation: Finding the best balance between efficacy and side effects.
• Regular Monitoring: Ongoing monitoring for progression or improvement.
• Functional Support: Occupational and physical therapy for functional impairments.
• Quality of Life: Addressing impact on quality of life and daily functioning.

Prevention Strategies

Prescribing Practices

• Risk-Benefit Analysis: Careful consideration of risks and benefits before prescribing.
• Lowest Effective Dose: Using the lowest effective dose of medications.
• Gradual Titration: Gradual increases in medication doses.
• Regular Review: Regular review of medication necessity and effectiveness.

Monitoring Protocols

• Baseline Assessment: Pre-treatment assessment of movement and neurological function.
• Regular Screening: Regular screening using standardised assessment tools.
• Early Detection: Early detection and intervention for emerging symptoms.
• Patient Education: Educating patients about potential side effects and when to report them.

Alternative Approaches

• Medication Selection: Choosing medications with lower risk profiles when possible.
• Non-Pharmacological Treatments: Using psychotherapy and other non-drug treatments when appropriate.
• Combination Strategies: Using lower doses of multiple medications rather than high doses of single medications.
• Personalised Medicine: Considering individual risk factors in treatment selection.

Special Populations

Elderly Patients

• Increased Risk: Higher risk for movement disorders in elderly patients.
• Dose Adjustments: Need for lower doses and more gradual titration.
• Polypharmacy: Increased risk from multiple medications and interactions.
• Functional Impact: Greater impact on mobility and independence.

Children and Adolescents

• Developmental Considerations: Impact on normal development and growth.
• School Functioning: Effects on academic performance and social functioning.
• Family Impact: Impact on family functioning and dynamics.
• Long-Term Effects: Potential long-term effects of early exposure.

Pregnant Women

• Fetal Considerations: Potential effects on fetal development.
• Treatment Decisions: Balancing maternal mental health needs with fetal safety.
• Monitoring: Increased monitoring during pregnancy.
• Postpartum: Considerations for breastfeeding and postpartum care.

Patients with Comorbidities

• Medical Comorbidities: Interactions with other medical conditions.
• Psychiatric Comorbidities: Impact on other mental health conditions.
• Substance Use: Interactions with alcohol and drug use.
• Cognitive Impairment: Special considerations for patients with dementia or cognitive impairment.

Prognosis and Outcomes

Factors Affecting Prognosis

• Early Detection: Earlier detection and treatment generally lead to better outcomes.
• Medication Changes: Ability to modify or discontinue causative medications.
• Symptom Severity: Severity of symptoms affects recovery potential.
• Patient Factors: Age, overall health, and other individual factors.

Recovery Patterns

• Acute Symptoms: Acute dystonia and parkinsonism often reversible with treatment.
• Akathisia: Usually improves with appropriate treatment and medication changes.
• Tardive Syndromes: May be partially or completely reversible, but can be persistent.
• Individual Variation: Significant individual variation in recovery patterns.

Long-Term Outcomes

• Functional Recovery: Many patients can achieve good functional recovery.
• Quality of Life: Treatment can significantly improve quality of life.
• Medication Management: Successful long-term medication management is often possible.
• Ongoing Monitoring: Need for ongoing monitoring and management.

Key Takeaways

Medication-Induced Movement Disorders are important side effects of psychiatric medications that require careful monitoring, early detection, and appropriate treatment. Understanding these conditions helps ensure safe and effective medication management.

Important points to remember:

• Movement disorders can develop at any time during medication treatment
• Early detection and intervention generally lead to better outcomes
• Many movement disorders are treatable and potentially reversible
• Regular monitoring using standardised tools is essential
• Balancing mental health treatment with movement disorder risk requires careful clinical judgment
• Healthcare providers and patients should work together to monitor for these side effects and address them promptly when they occur, ensuring both effective mental health treatment and optimal quality of life.